TPG Capital in Acquisition of Immucor
July 05, 2011
A Cleary Gottlieb team in New York is representing Goldman Sachs, as financial advisor to Immucor, in the sale of that company to an affiliate of TPG Capital for $1.97 billion or $27 per share in cash using a dual track tender offer/one-step merger structure. A separate Cleary Gottlieb team in Brussels is advising TPG on European antitrust matters relating to this transaction. The transaction, announced on July 5, 2011, is expected to close in the second half of 2011.
Immucor is a global in vitro diagnostics company specializing in the area of pre-transfusion diagnostics.